CytomX Therapeutics Inc [CTMX] stock is trading at $0.67, up 0.45%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CTMX shares have gain 5.83% over the last week, with a monthly amount drifted -14.13%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CytomX Therapeutics Inc [NASDAQ: CTMX] stock has seen the most recent analyst activity on May 28, 2024, when Piper Sandler upgraded its rating to a Overweight and also boosted its price target to $3.50 from $2.25. Previously, Wedbush upgraded its rating to Outperform on May 09, 2024, and kept the price target unchanged to $8. On May 06, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $8 on the stock. JP Morgan upgraded its rating to a Neutral. BMO Capital Markets downgraded its rating to a Market Perform and reduced its price target to $2.60 on November 14, 2022. Wedbush downgraded its rating to Neutral for this stock on July 07, 2022, and downed its price target to $2. In a note dated July 07, 2022, Piper Sandler downgraded an Neutral rating on this stock and revised its target price from $10 to $1.50.
CytomX Therapeutics Inc [CTMX] stock has fluctuated between $0.56 and $5.85 over the past year. Currently, Wall Street analysts expect the stock to reach $3.47 within the next 12 months. CytomX Therapeutics Inc [NASDAQ: CTMX] shares were valued at $0.67 at the most recent close of the market. An investor can expect a potential return of 417.91% based on the average CTMX price forecast.
Analyzing the CTMX fundamentals
CytomX Therapeutics Inc [NASDAQ:CTMX] reported sales of 138.10M for the trailing twelve months, which represents a growth of 43.17%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.26, Equity is -1.47 and Total Capital is 0.72. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-20.58.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6527 points at the first support level, and at 0.6356 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6843, and for the 2nd resistance point, it is at 0.6988.
Ratios To Look Out For
For context, CytomX Therapeutics Inc’s Current Ratio is 1.25. As well, the Quick Ratio is 1.25, while the Cash Ratio is 0.44. Considering the valuation of this stock, the price to sales ratio is 0.39 and price to earnings (TTM) ratio is 1.70.
Transactions by insiders
Recent insider trading involved McCarthy Sean A., CEO, that happened on Mar 18 ’25 when 37656.0 shares were sold. Chief Financial Officer, Ogden Christopher completed a deal on Mar 18 ’25 to sell 8551.0 shares. Meanwhile, Chief Medical Officer Chu Yu-Waye sold 4025.0 shares on Mar 18 ’25.
